002688 Share Price Performance
CN¥6.69
2.27 (51.36%)
Price CN¥6.69
Share PriceCN¥6.69
Jinhe Biotechnology CO., LTD. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
002688 Community Narratives
There are no narratives available yet.
Recent 002688 News & Updates
Jinhe Biotechnology CO., LTD. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 30, 2025
- Earnings per share (EPS)
- 0.20
- Gross Margin
- 32.27%
- Net Profit Margin
- 5.46%
- Debt/Equity Ratio
- 89.1%
Jinhe Biotechnology CO., LTD. Competitors
Snowflake Analysis
Proven track record with adequate balance sheet and pays a dividend.
2 Risks
3 Rewards
About 002688
- Founded
- 1990
- Employees
- 2476
- CEO
- WebsiteView website
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China. It offers chlortetracycline feed grade, an antimicrobial drug for the inhibition and treatment of white dysentery, enteritis, pneumonia, typhoid, paratyphoid, cholera, etc. in poultry and livestock; and chlortetracycline hydrochloride for the inhibition and treatment of pullorum disease, typhoid, and swine enteritis, as well as bacterial diseases, including paratyphoid and cholera. The company also exports its products to the China, the United States, Canada, Europe, South America, Southeast Asia, India, Vietnam, and internationally. Jinhe Biotechnology CO., LTD. was founded in 1990 and is based in Dalian, China.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Chinese Market Performance
- 7 Days: 0.5%
- 3 Months: 17.0%
- 1 Year: 24.1%
- Year to Date: 26.2%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. Meanwhile, the market is actually up 24% over the past year. Earnings are forecast to grow by 27% annually. Market details ›